American Heart Association's High Blood Pressure Research Scientific Sessions

Healio brings you the highlights from the American Heart Association's High Blood Pressure Research Scientific Sessions. Refer back to this page often for the latest news from the AHA High Blood Pressure Research Scientific Sessions, perspectives and interviews with leading researchers and clinicians, and to review archives of past meetings.

Meeting News Coverage

AHA Conference Blog: Tempered enthusiasm for novel approaches to address cholesterol

Cardiology Today, December 2012
Meeting News Coverage

SCIPIO: Cardiac stem cells may be effective HF treatment

Cardiology Today, December 2012
LOS ANGELES — Patients with HF who received an infusion of their own cardiac stem cells experienced significant increases in viable…
Meeting News CoveragePerspectivePublication Exclusive

FORWARD, OPERA: Omega-3 fatty acids do not reduce AF occurrence

Cardiology Today, January 2013
LOS ANGELES — Omega-3 fatty acid supplementation before and after cardiac surgery did not decrease risk for postoperative atrial fibrillation…
Meeting News CoveragePerspectivePublication Exclusive

FORWARD, OPERA: Omega-3 fatty acids do not reduce AF occurrence

Endocrine Today, December 2012
LOS ANGELES — Omega-3 fatty acid supplementation before and after cardiac surgery did not decrease risk for postoperative atrial fibrillation…
Meeting News Coverage

RUTHERFORD: PCSK9 inhibition improved LDL in patients with familial hypercholesterolemia

November 6, 2012
LOS ANGELES — When administered every 4 weeks, AMG 145 provided rapid and significant reductions to LDL and was well tolerated by patients with…
Meeting News CoveragePerspectivePublication Exclusive

CPORT-E: PCI costs higher in hospitals without onsite cardiac surgery unit

Cardiology Today, December 2012
LOS ANGELES — An economic analysis of the CPORT-E trial revealed that PCI costs were higher when performed at hospitals without an onsite…
Meeting News CoveragePerspectivePublication Exclusive

GAUSS: PCSK9 antibody reduced LDL in statin-intolerant patients

Cardiology Today, December 2012
LOS ANGELES — Patients at CV risk who are unable to tolerate effective doses of statins experienced reductions in LDL levels of up to 51% with…
Meeting News Coverage

UMPIRE: Polypill strategy improved adherence, systolic BP, LDL

Endocrine Today, December 2012
LOS ANGELES — Patients with CVD who were assigned a fixed-dose combination therapy of statin, antiplatelet and BP-lowering drugs experienced…
Meeting News CoveragePerspectivePublication Exclusive

Daily multivitamin failed to reduce major CVD risk in middle-aged men

Endocrine Today, December 2012
LOS ANGELES — Despite common usage of multivitamins in the United States, recent data from the Physicians’ Health Study II suggest that…
Meeting News CoveragePerspectivePublication Exclusive

Dalcetrapib increased HDL, did not reduce risk for CV events

Cardiology Today, December 2012
LOS ANGELES — New data from the dal-OUTCOMES trial reveal that dalcetrapib, a cholesterol ester transfer protein inhibitor, increased HDL…